Drug membrane transport enhancement using high energy drug polyvinylpyrrolidone (PVP) co-precipitates
dc.contributor.author | Corrigan, O. I. | en_US |
dc.contributor.author | Farvar, M. A. | en_US |
dc.contributor.author | Higuchi, William I. | en_US |
dc.date.accessioned | 2006-04-07T17:24:59Z | |
dc.date.available | 2006-04-07T17:24:59Z | |
dc.date.issued | 1980-05 | en_US |
dc.identifier.citation | Corrigan, O. I., Farvar, M. A., Higuchi, W. I. (1980/05)."Drug membrane transport enhancement using high energy drug polyvinylpyrrolidone (PVP) co-precipitates." International Journal of Pharmaceutics 5(3): 229-238. <http://hdl.handle.net/2027.42/23253> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6T7W-4772KDJ-7/2/24c237b301bc51f6d5892b7e21abb5fa | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/23253 | |
dc.description.abstract | Dissolution rate data obtained with sulfathiazole-povidone(PVP) co-precipitates and hydrocortisone-povidone co-precipitates were compared to cellophane membrane diffusion data obtained with the co-precipitates. The hypothesis, that the rate-limiting drug phases in the co-precipitate dissolution experiments were high energy amorphous phases of the drug, was tested. In regions of the dissolution rate studies where the carrier effects due to the PVP-drug complexes were small, the dissolution rates for the two PVP-drug systems agreed well with the results of the membrane diffusion experiments. The normalized fluxes were found to be about 3.5 for the high energy phase of sulfathiazole and 14-18 for that of hydrocortisone. | en_US |
dc.format.extent | 888654 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Drug membrane transport enhancement using high energy drug polyvinylpyrrolidone (PVP) co-precipitates | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | College of Pharmacy, The University of Michigan, Ann Arbor, Mich. 48109, U.S.A. | en_US |
dc.contributor.affiliationum | College of Pharmacy, The University of Michigan, Ann Arbor, Mich. 48109, U.S.A. | en_US |
dc.contributor.affiliationum | College of Pharmacy, The University of Michigan, Ann Arbor, Mich. 48109, U.S.A. | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/23253/1/0000186.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0378-5173(80)90130-1 | en_US |
dc.identifier.source | International Journal of Pharmaceutics | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.